Sign in
Taking peopleNo phase

Efficacy of SGLT2 Inhibitors in Adults With Sepsis

Key facts

Who runs it
Hospital Authority, Hong Kong
Where
Hong Kong3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
60 people, planned
Started
5 Mar 2025
Expected to end
28 Feb 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Empagliflozin 10 MG
  • Placebo
Record updated
19 March 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Aged 18 years or above
  • New onset of sepsis within 48 hours defined according to the Sepsis-3 criteria. (≥2 SOFA)
  • Provision of signed and dated informed consent form from participant or surrogate
  • Ability to take and adhere to oral and enteral medication regimen
  • Willingness to comply

Who cannot take part

  • Current or recent use of SGLT2 inhibitors (within 12wks prior to randomization)
  • Treatment with another investigational drug or other interventions within 30 days prior to trial
  • History of ketoacidosis
  • Gastrointestinal surgery or GI absorption / malabsorption disorder
  • Known allergic or hypersensitivity reactions to any SGLT2 inhibitors
  • Impaired renal function
  • Clinically unstable or in refractory hypotension
  • Pregnancy

This trial is currently available in Hong Kong.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows:

Read full original descriptionShow less

(i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis.

(ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.

The 2 groups in the trial

  • SGLT2 inhibitor empagliflozinTreatment being tested

    10mg daily from recruitment to hospital discharge

    Treatment: Empagliflozin 10 MG

  • PlaceboPlacebo, for comparison

    1 tablet daily from recruitment to hospital discharge

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Sepsis: A Feasibility Study for a Multicenter Double-Blind Randomized Placebo-Controlled Trial
Record updated
19 March 2025